Amgen

Amgen, a US-based Pharmaceutical Preparation Manufacturing company, reported approximately 1.9 billion kg CO2e in total carbon emissions for 2024. This includes Scope 1 emissions of about 147.4 million kg CO2e, Scope 2 emissions of around 14 million kg CO2e (market-based), and Scope 3 emissions of approximately 1.7 billion kg CO2e. Key contributors to Scope 3 emissions include purchased goods and services (around 945.8 million kg CO2e), downstream transportation and distribution (approximately 213.1 million kg CO2e), and capital goods (about 221 million kg CO2e).

Amgen has set ambitious climate commitments, with its Science-Based Targets initiative (SBTi) approved targets classified as consistent with a 1.5°C warming scenario. Amgen is committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 55% by 2027 from a 2019 base year. This target also includes increasing annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, continuing through 2030. Furthermore, Amgen aims for 73% of its suppliers, by spend, covering upstream purchased goods and services and capital goods, to have science-based targets by 2027.

The company is also striving for 100% renewable electricity use at all feasible operations by 2027, which is expected to result in an approximate 50% reduction in operational carbon emissions. Additionally, Amgen aims to achieve carbon neutrality for its owned and operated facilities and operations (Scope 1 and 2) by 2027. By 2023, Amgen had achieved 54% of its targeted reductions for Scope 1 and 2 carbon emissions from its 2019 baseline.